Haematologic Technologies Is Now Prolytix, Integrating to Support Growing Large Molecule Market
ESSEX JUNCTION, VT; March 3, 2022 – Haematologic Technologies (“HT”), a global analytical and bioanalytical leader for large molecule drug development, today announced they’ll be operating under the new name,…
Haematologic Technologies Announces John Strokis as Vice President, Quality
John Strokis to Lead the Quality Initiatives for the Company Through Next Phase of Growth ESSEX JUNCTION, Vt., Dec. 16, 2021 /PRNewswire/ — Haematologic Technologies (“HT”), a global leader in large molecule bioanalysis…
Haematologic Technologies Announces David Sunseri, Ph.D., as President and Chief Executive Officer
David Sunseri, Ph.D. to Lead the Company Through Next Phase of Growth March 1, 2021 – Essex Junction, VT: Haematologic Technologies (“HTI”), a global leader in large molecule bioanalysis and biologic…
Haematologic Technologies Adds a High Resolution Mass Spectrometry Lab
Expanded Capabilities add to HTI’s Growing Large Molecule Bioanalysis Services Business September 30th, 2020 Essex Junction, VT –Haematologic Technologies (HTI), a leading protein chemistry company providing products and analytical services…